Ginkgo Bioworks Holdings, Inc. (New York Stock Exchange:DNA)
| Market Cap | 443.55M-36.9% |
| Revenue (ttm) | 111.86M-51.5% |
| Net Income | -290.80M+7.7% |
| EPS | -5.02+15.3% |
| Shares Out | 65.32M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 891,007 |
| Open | 6.83 |
| Previous Close | 6.94 |
| Day's Range | 6.71 - 6.93 |
| 52-Week Range | 5.37 - 17.58 |
| Beta | 1.77 |
| Analysts | Buy |
| Price Target | 5.00(-26.36%) |
| Earnings Date | Nov 5, 2026 |
About DNA
Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops a platform for cell engineering in the United States. It operates through the Cell Engineering and Biosecurity segments. The company offers cell engineering research and development solutions, as well as cell engineering tools comprising functional genomics, antibody developability, and small molecule developability, artificial intelligence models, and reconfigurable automation cart systems on its platform for use in the research, development, and commercialization of engineered organisms and derived products. It also provides biomonitoring and bioinformatics support services through Canopy, which generates genomic data from strategically positioned nodes through biomonitoring programs; and Horizon, a digital surveillance, analytics, and insights platform that detects and monitors biothreats. In addition, the company offers genetic medicine R&D, protein engineering, bioprocess development, crop nutrition and protection solutions, and plant trait optimization. The company serves pharmaceutical and biotechnology, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$DNA stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in DNA holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by DNA's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
DNA Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New DNA patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to DNA from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in DNA
| ETF | Est. Holding Size |
|---|---|
| VTIVanguard Morningstar Total Stock Market ETF | $12.05M |
| IWMiShares Russell 2000 ETF | $8.56M |
| VXFVanguard Extended Market ETF | $4.46M |
| IWNiShares Russell 2000 Value ETF | $3.08M |
| IBBiShares Biotechnology ETF | $2.62M |
| THNQROBO Global Artificial Intelligence ETF | $2.49M |
Estimated from each fund’s disclosed top holdings × AUM
DNA Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from DNA’s recent data — informational, not investment advice
Insider Score
Our 0–100 Insider Score and the signals behind it.
The live Insider Score and its full factor breakdown are included with Insider Access.
Unlock Insider Score